Skip to main content

Table 1 Patient characteristics classified by renal function

From: Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study

Variable

Renal function classification

P-value

Total

(n = 524)

Normal

Mild

Moderate

Severe

(n = 153)

(n = 222)

(n = 117)

(n = 32)

Age (years)

59.0 ± 10.3

70.5 ± 8.3

75.6 ± 8.6

78.0 ± 10.2

< 0.001

68.7 ± 11.3

Sex, male/female (n)

77/76

135/87

69/48

22/10

0.119

303/221

Body weight (kg)

60.3 ± 11.9

55.9 ± 10.3

50.9 ± 11.4

49.4 ± 12.2

< 0.001

55.7 ± 11.8

(n = 142)

(n = 191)

(n = 99)

(n = 30)

(n = 462)

Serum creatinine (mg/dL)

0.60 ± 0.12

0.76 ± 0.17

1.00 ± 0.27

2.14 ± 1.23

< 0.001

0.85 ± 0.50

Creatinine clearance (mL/min)

97.8 ± 14.4

64.5 ± 8.4

41.5 ± 5.6

21.2 ± 6.0

< 0.001

66.4 ± 25.6

Serum calcium level (mg/dL)

9.0 ± 0.6

9.2 ± 0.8

9.4 ± 1.1

9.9 + 2.3

0.358

9.2 ± 1.0

Albumin-adjusted serum calcium level (mg/dL)

9.6 ± 0.6

9.6 ± 0.8

10.1 ± 1.2

10.9 + 2.4

< 0.001

9.8 ± 1.1

(n = 149)

(n = 218)

(n = 113)

(n = 32)

 

(n = 512)

Serum albumin (g/dL)

3.6 ± 0.7

3.6 ± 0.7

3.3 ± 0.6

3.1 ± 0.7

< 0.001

3.5 ± 0.7

(n = 149)

(n = 218)

(n = 113)

(n = 32)

 

(n = 512)

Serum phosphorus (mg/dL)

3.3 + 0.8

3.4 + 0.7

3.3 + 0.6

3.8 ± 0.8

0.108

3.4 ± 0.7

(n = 68)

(n = 94)

(n = 59)

(n = 23)

 

(n = 244)

Cancer type Lung cancer

61 (40)

93 (42)

52 (44)

13 (41)

0.084

219 (42)

 Breast cancer

36 (24)

41 (18)

13 (11)

2 (6)

 

92 (18)

 Prostate cancer

17 (11)

42 (19)

21 (18)

8 (25)

 

88 (17)

 Other

39 (25)

46 (21)

31 (26)

9 (28)

 

125 (24)

Prophylactic administration

      

 Natural vitamin D ± calcium

137 (90)

193 (87)

92 (79)

19 (59)

< 0.001

441 (84)

 Active vitamin D ± calcium

7 (5)

7 (3)

6 (5)

7 (22)

 

27 (5)

 Calcium only

0 (0)

0 (0)

0 (0)

1 (3)

 

1 (0.2)

 None

9 (6)

22 (10)

19 (16)

5 (16)

 

55 (10)

  1. Values in parentheses represent percentages